Want to join the conversation?
$CELG's revenue from Revlimid grew 11.8% to $1.45Bil in 3Q15 from last year and Abraxane revenue rose 8.3% to $229.9MM. Pomalyst/Imnovid revenue jumped 41.6% to $256.5MM. Otezla revenue was $138.7MM in 3Q15, while Vidaza revenue fell 6.5% to $147.6MM and Thalomid revenue declined 13.1% to $45.1MM. Istodax revenue rose 10.2% to $17.3MM.
Planned to give Apple AirPods as a Christmas present to my beloved one. Looks like I need backup plans as $AAPL is delaying the release..!!
When you fall hard, I think you stay there for a long time.. I am looking at you $FTNT! After it released the earnings, the share price slipped and is staying around $30 for a long time.
$FOXA just entered into a preliminary deal with Sky plc under which it will acquire all shares, or should I say remaining shares for a total value of $23 billion. The sleeping fox catches no poultry, but this fox just caught something that’s a lot bigger than poultry.